Novel Findings for the Development of Drug Therapy for Various Liver Diseases:Liver Microsomal Triglyceride Transfer Protein Activator May Be a Possible Therapeutic Agent in Non-alcoholic Steatohepatitis
-
- Fujita Koji
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Imajo Kento
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Shinohara Yoshiyasu
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Nozaki Yuichi
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Wada Koichiro
- Department of Pharmacology, Graduate School of Dentistry, Osaka University, Japan
-
- Yoneda Masato
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Endo Hiroki
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Takahashi Hirokazu
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Abe Yasunobu
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Inamori Masahiko
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Shimamura Takeshi
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Kobayashi Noritoshi
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Kirikoshi Hiroyuki
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Kubota Kensuke
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Saito Satoru
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
-
- Nakajima Atsushi
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan
Bibliographic Information
- Other Title
-
- Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis
Search this article
Abstract
The factors involved in the progression of non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH) are not fully understood and thus it is urgently needed to elucidate these factors. Steatosis is not causal in the development of NASH, but rather it sensitizes the liver to the damaging effects of second hits such that stressors innocuous to a healthy liver lead to the development of NASH in the steatotic liver. In the previous study, most of the hepatic lipid metabolite profiles were similar in the NAFL and NASH groups. However, very-low-density lipoprotein (VLDL) synthesis, especially hepatic microsomal triglyceride transfer protein (MTP) mRNA expression, was impaired in the NASH group. Moreover, NASH showed significantly higher incidence of minor alley appearance compared with NAFL, indicating the possibility of association between NASH pathogenesis and decreased congenital MTP activity. MTP is one of the enzymes that transfer triglycerides to nascent apolipoprotein B, producing VLDL and removing lipid from the hepatocyte. A growing body of literature suggests that the measurement of hepatic MTP expression may be helpful for diagnosis; and moreover, hepatic MTP activator may be a possible therapeutic agent for the treatment of NASH.
Journal
-
- Journal of Pharmacological Sciences
-
Journal of Pharmacological Sciences 115 (3), 270-273, 2011
The Japanese Pharmacological Society
- Tweet
Keywords
Details
-
- CRID
- 1390282680154747776
-
- NII Article ID
- 10029892362
-
- NII Book ID
- AA11806667
-
- ISSN
- 13478648
- 13478613
-
- NDL BIB ID
- 11009946
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed